MedDataX Logo

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

NCT ID: NCT00637637

Last Updated: 2013-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether external-beam radiation therapy is more effective with or without indinavir and ritonavir in treating patients with brain metastases.

PURPOSE: This randomized phase II trial is studying external-beam radiation therapy alone to see how well it works compared to external-beam radiation therapy given together with indinavir and ritonavir in treating patients with brain metastases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare the efficacy, in terms of time to treatment failure at CNS level and 4-months treatment failure rate, in patients with brain metastases treated with external-beam radiotherapy in combination with indinavir sulfate and ritonavir versus external-beam radiotherapy alone.
* Prospectively investigate the efficacy of a potentially antiangiogenic agent, indinavir sulfate.
* Investigate the antineoplastic activity of indinavir sulfate in combination with ionizing radiation in cancer patients with metastatic disease to the brain.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo radiotherapy to the brain once daily, 5 days a week for 2 weeks (10 doses total). Patients also receive oral indinavir sulfate and oral ritonavir twice daily for 35 days beginning at day 1 of radiotherapy.
* Arm II: Patients undergo radiotherapy to the brain once daily, 5 days a week for 2 weeks (10 doses total).

Patients complete quality of life questionnaires, including QOL-30 and the Mini Mental Status Examination, at baseline, 2 weeks after completion of radiotherapy, and at 1 and 3 months after completion of study treatment.

After completion of study treatment, patients are followed periodically for at least 4 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

tumors metastatic to brain stage IV adenoid cystic carcinoma of the oral cavity stage IV adrenocortical carcinoma stage IV adult Burkitt lymphoma stage IV adult diffuse large cell lymphoma stage IV adult diffuse mixed cell lymphoma stage IV adult diffuse small cleaved cell lymphoma stage IV adult Hodgkin lymphoma stage IV adult immunoblastic large cell lymphoma stage IV adult lymphoblastic lymphoma stage IV adult T-cell leukemia/lymphoma stage IV anal cancer stage IV basal cell carcinoma of the lip stage IV bladder cancer stage IV borderline ovarian surface epithelial-stromal tumor stage IV breast cancer stage IV childhood anaplastic large cell lymphoma stage IV childhood Hodgkin lymphoma stage IV childhood large cell lymphoma stage IV childhood liver cancer stage IV childhood lymphoblastic lymphoma stage IV childhood small noncleaved cell lymphoma stage IV chronic lymphocytic leukemia stage IV colon cancer stage IV cutaneous T-cell non-Hodgkin lymphoma stage IV esophageal cancer stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity stage IV follicular thyroid cancer stage IV gastric cancer stage IV grade 1 follicular lymphoma stage IV grade 2 follicular lymphoma stage IV grade 3 follicular lymphoma stage IV hypopharyngeal cancer stage IV inverted papilloma of the paranasal sinus and nasal cavity stage IV laryngeal cancer stage IV lip and oral cavity cancer stage IV lymphoepithelioma of the nasopharynx stage IV lymphoepithelioma of the oropharynx stage IV mantle cell lymphoma stage IV marginal zone lymphoma stage IV midline lethal granuloma of the paranasal sinus and nasal cavity stage IV mucoepidermoid carcinoma of the oral cavity stage IV mycosis fungoides/Sezary syndrome stage IV nasopharyngeal cancer stage IV non-small cell lung cancer stage IV oropharyngeal cancer stage IV ovarian epithelial cancer stage IV pancreatic cancer stage IV papillary thyroid cancer stage IV paranasal sinus and nasal cavity cancer stage IV penile cancer stage IV prostate cancer stage IV rectal cancer stage IV renal cell cancer stage IV salivary gland cancer stage IV small lymphocytic lymphoma stage IV squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the nasopharynx stage IV squamous cell carcinoma of the oropharynx stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity stage IV endometrial carcinoma stage IV verrucous carcinoma of the larynx stage IV verrucous carcinoma of the oral cavity stage IVB vulvar cancer stage IV Wilms tumor stage IVB cervical cancer stage IVB vaginal cancer metastatic adult malignant fibrous histiocytoma of bone metastatic childhood malignant fibrous histiocytoma of bone metastatic gastrointestinal carcinoid tumor metastatic parathyroid cancer metastatic pheochromocytoma metastatic squamous neck cancer with occult primary squamous cell carcinoma metastatic squamous neck cancer with occult primary metastatic transitional cell cancer of the renal pelvis and ureter disseminated neuroblastoma unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific tongue cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

indinavir sulfate

Intervention Type DRUG

ritonavir

Intervention Type DRUG

radiation therapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed metastatic cancer with brain metastases

* Biopsy of brain metastases is not required
* All cancer types allowed, except for the following:

* Prostatic adenocarcinoma
* Sarcoma
* Melanoma
* Germ cell carcinoma,
* Small-cell lung cancer
* Measurable disease by MRI of the brain
* Not requiring immediate surgical decompression (may qualify after surgery, if remaining measurable brain lesions)

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2 (corresponds to recursive partitioning analysis groups I or II)
* Life expectancy \> 4 months
* Able to understand the aim of trial and to comply with follow-up
* No HIV seropositivity

PRIOR CONCURRENT THERAPY:

* Prior dexamethasone allowed provided it is tapered before initiation of study radiotherapy
* Not requiring cytotoxic treatment within 3 months after study radiotherapy
* At least 1 week since prior and no concurrent phenytoin
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oncology Institute of Southern Switzerland

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ilja Ciernik, MD

Role: PRINCIPAL_INVESTIGATOR

Oncology Institute of Southern Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Cantonal Universitaire de Geneve

Geneva, , Switzerland

Site Status RECRUITING

Oncology Institute of Southern Switzerland - Lugano

Lugano, , Switzerland

Site Status RECRUITING

UniversitaetsSpital Zuerich

Zurich, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CDR0000587517

Identifier Type: REGISTRY

Identifier Source: secondary_id

IOSI-RO0402

Identifier Type: -

Identifier Source: org_study_id